Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19087028 | 0.84 | ALDH1A1 (0.50) | SIGMAR1LMNAPOLBACHEDRD4 | |
| SCHEMBL6621542 | 0.81 | SIGMAR1 (0.52) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL19116976 | 0.79 | SIGMAR1 (0.50) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL19077902 | 0.78 | SIGMAR1 (0.48) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL10640414 | 0.77 | SIGMAR1 (0.52) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL5870967 | 0.76 | SIGMAR1 (0.50) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL10914396 | 0.76 | CYP2D6 (0.47) | SIGMAR1LMNAPOLBMC4R | |
| SCHEMBL13400321 | 0.76 | SIGMAR1 (0.46) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL12612421 | 0.75 | SIGMAR1 (0.48) | SIGMAR1LMNAPOLBMC4RACHE | |
| SCHEMBL11136071 | 0.75 | SLC6A1 (0.57) | SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| CN-106470993-B | The azepine quinazoline inhibitor of Atypical protein kinase C | 癌症研究科技有限公司 | 2019-08-27 | — | — | CN | disclosed |
| EP-3059239-B1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-1740572-A1 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005103031-A1 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | SIGMAR1 2868/4885LMNA 3280/4885POLB 891/4885 |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | SIGMAR1 3027/4885LMNA 2699/4885POLB 2645/4885 |
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, GPR119 | SIGMAR1 74/4885LMNA 2571/4885POLB 4358/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | SIGMAR1 1018/4885LMNA 2488/4885POLB 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.